Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.74% ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Cargo Therapeutics, a Bay Area biotech firm, is laying off half its staff after having to shut down a promising drug ...

The California-based company estimates that restructuring activities to close AK006 development will cost around $34 million to $38 million, with a major portion of these payments paid over in the ...

Allakos said it plans to explore strategic alternatives, adding that it expects its cash, equivalents and investments will total $35 million to $40 million by the end of June. The company now sports a ...

In a turbulent market environment, Allakos Inc . (NASDAQ:ALLK) stock has touched a new 52-week low, reaching a price level of just $0.3. While the stock appears undervalued according to InvestingPro ...

SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria ...

Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it ...